OTCMKTS:INVVY - INDIVIOR PLC/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding INDIVIOR PLC/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.44 +0.09 (+3.83 %) (As of 01/28/2020 04:00 PM ET) Add Compare Today's Range$2.42Now: $2.44▼$2.4650-Day Range$2.30MA: $2.54▼$2.8352-Week Range$1.98Now: $2.44▼$7.75Volume7,191 shsAverage Volume6,228 shsMarket Capitalization$355.41 millionP/E Ratio1.48Dividend YieldN/ABeta-0.19 ProfileAnalyst RatingsAdvanced ChartEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. Read More… Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:INVVY Previous SymbolNASDAQ:INVVY CUSIPN/A CIKN/A Webhttp://www.indivior.com/ Phone804-379-1090Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E Ratio1.48 Forward P/E Ratio1.81 P/E GrowthN/A Sales & Book Value Annual Sales$1.01 billion Price / Sales0.35 Cash Flow$2.28 per share Price / Cash Flow1.07 Book Value$0.45 per share Price / Book5.42Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees915 Outstanding Shares145,660,000Market Cap$355.41 million Next Earnings Date2/13/2020 (Estimated) OptionableNot Optionable Receive INVVY News and Ratings via Email Sign-up to receive the latest news and ratings for INVVY and its competitors with MarketBeat's FREE daily newsletter. OTC:INVVY Rates by TradingView INDIVIOR PLC/S (OTCMKTS:INVVY) Frequently Asked Questions What is INDIVIOR PLC/S's stock symbol? INDIVIOR PLC/S trades on the OTCMKTS under the ticker symbol "INVVY." When is INDIVIOR PLC/S's next earnings date? INDIVIOR PLC/S is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for INDIVIOR PLC/S. Has INDIVIOR PLC/S been receiving favorable news coverage? Media coverage about INVVY stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. INDIVIOR PLC/S earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for INDIVIOR PLC/S. Who are some of INDIVIOR PLC/S's key competitors? Some companies that are related to INDIVIOR PLC/S include TG Therapeutics (TGTX), Endo International (ENDP), Dicerna Pharmaceuticals (DRNA), Intra-Cellular Therapies (ITCI), Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN), IGM Biosciences (IGMS), Madrigal Pharmaceuticals (MDGL), ZEALAND PHARMA/S (ZEAL), Myovant Sciences (MYOV), Rocket Pharmaceuticals (RCKT), Athenex (ATNX), Opko Health (OPK), Enanta Pharmaceuticals (ENTA) and Portola Pharmaceuticals (PTLA). What other stocks do shareholders of INDIVIOR PLC/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other INDIVIOR PLC/S investors own include Indivior (INDV), Swedbank (SWDBY), Amphastar Pharmaceuticals (AMPH), Amyris (AMRS), Chiasma (CHMA), HEXO (HEXO), Intel (INTC), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO) and Ulta Beauty (ULTA). Who are INDIVIOR PLC/S's key executives? INDIVIOR PLC/S's management team includes the folowing people: Mr. Shaun Thaxter, CEO & Exec. DirectorMr. Mark Crossley, CFO & Exec. DirectorDr. Christian Heidbreder, Chief Scientific OfficerMr. Ingo Elfering, Chief Information & Innovation OfficerMr. Jason Thompson, VP of Investor Relations How do I buy shares of INDIVIOR PLC/S? Shares of INVVY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is INDIVIOR PLC/S's stock price today? One share of INVVY stock can currently be purchased for approximately $2.44. How big of a company is INDIVIOR PLC/S? INDIVIOR PLC/S has a market capitalization of $355.41 million and generates $1.01 billion in revenue each year. The company earns $275 million in net income (profit) each year or $1.80 on an earnings per share basis. INDIVIOR PLC/S employs 915 workers across the globe.View Additional Information About INDIVIOR PLC/S. What is INDIVIOR PLC/S's official website? The official website for INDIVIOR PLC/S is http://www.indivior.com/. How can I contact INDIVIOR PLC/S? INDIVIOR PLC/S's mailing address is 10710 Midlothian Turnpike, North Chesterfield VA, 23235. The company can be reached via phone at 804-379-1090 or via email at [email protected] MarketBeat Community Rating for INDIVIOR PLC/S (OTCMKTS INVVY)Community Ranking: 1.9 out of 5 ()Outperform Votes: 111 (Vote Outperform)Underperform Votes: 177 (Vote Underperform)Total Votes: 288MarketBeat's community ratings are surveys of what our community members think about INDIVIOR PLC/S and other stocks. Vote "Outperform" if you believe INVVY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVVY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/28/2020 by MarketBeat.com StaffFeatured Article: Why do earnings reports matter?
